This study focuses on patients with acute ischemic stroke and atrial fibrillation, a condition where the heart beats irregularly. The research aims to determine if early treatment to control heart rhythm, along with standard care, can reduce the risk of cardiovascular problems compared to standard care alone.
The study will use several heart rhythm control medications including dronedarone hydrochloride, propafenone hydrochloride, amiodarone hydrochloride, and flecainide acetate. These medications are taken by mouth in tablet form and work to help regulate the heart’s rhythm. The maximum daily doses range from 300 to 800 milligrams, depending on the specific medication used.
During the study, patients will be monitored for various heart and blood vessel-related health events, including additional strokes, heart problems requiring hospitalization, and changes in heart function. The study will also track patients’ overall well-being, including their ability to perform daily activities, quality of life, and mental function. Participants will be followed for up to 24 months after starting treatment.
Germany 
Spain 
The Netherlands 
